The Technical Analyst
SPDR Series Trust S&P [XBI]
Exchange: NYSE Sector: Real Estate
SPDR Series Trust S&P Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.06% $89.06
America/New_York / 9 mai 2024 @ 12:57
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6 259.44 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 70.28 mill |
| Avg Daily Volume: | 11.60 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 30.55 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 13.52 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 86.74 - 91.52 ( +/- 2.68%) |
| ATR Model: 14 days |
Forecast:
14:36 - $89.24
Live Trading Signals (every 1 min)
Forecast
1: 13:06 - $89.08
Forecast 2: 13:56 - $89.20
Forecast 3: 14:36 - $89.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $89.06 (-0.06% ) |
| Volume | 4.20 mill |
| Avg. Vol. | 11.60 mill |
| % of Avg. Vol | 36.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XBI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XBI
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Latest News
2024-04-30 15:03:39 - Seeking Alpha
XBI: The 2 Things Biotech Needs To Move Higher
The biotech sector has experienced significant volatility but has returned around the same as the risk-free return from the 10-Year Treasury over the past year. There are two key items that will determine the direction of small and midcap biotech stocks in the months and quarters ahead. These are highlighted in the paragraphs below about SPDR® S&P Biotech ETF.
2024-04-23 07:21:21 - Zacks Investment Research
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Making its debut on 01/31/2006, smart beta exchange traded fund SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.
2024-04-19 11:29:12 - Seeking Alpha
XBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF Forever
SPDR S&P Biotech ETF offers a buying opportunity after a recent decline and trades close to the 200-day moving average. XBI has a strong long-term track record, providing generous total returns for shareholders. The biotech sector is seeing increased levels of merger and acquisition deals, indicating potential undervaluation in biotech stocks.
2024-04-03 13:47:03 - CNBC Television
Under-the-radar biotech bets
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
2024-04-02 16:30:04 - InvestorPlace
5 Healthcare Stocks to Buy for 2024
What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.
2024-03-28 14:56:04 - Zacks Investment Research
2 Top Biotech Buyout Candidates
After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.
2024-03-27 13:07:58 - InvestorPlace
3 Biotech Stocks to Buy on the Dip: March 2024
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.
2024-03-25 07:20:24 - Zacks Investment Research
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.
2024-03-20 04:50:32 - Seeking Alpha
XBI: Biotech Is A Strong Buy As M&A Activity Picks Up (Rating Upgrade)
Shares of biotechnology companies have been lagging behind the S&P 500 Index. This underperformance of XBI relative to the S&P 500, however, has only made the opportunity even more attractive to us. Evidence of improving fundamentals and rising mergers and acquisitions (M&A) activity within the biotechnology space has been underappreciated by investors.
2024-03-19 14:45:52 - InvestorPlace
3 Biotech ETFs Overdue for a Bounce
Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon.